Skip to main content

Table 4 Subgroup analyses for the outcome of event-free survival

From: Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

Subgroups No. of studies HR (95% CI) I2 (P value)
Population
 Children 6 5.62 (3.75–8.42) 3.2% (0.40)
 Mixed adult and children 2 3.60 (1.72–7.51) 65.2% (0.09)
Design
 Prospective 5 5.33 (2.88–9.86) 57.6% (0.05)
 Retrospective 3 4.59 (2.89–7.27) 0 (0.73)
Detection method
 PCR 6 4.97 (2.93–8.44) 49.2% (0.08)
 FC 2 4.77 (3.31–6.87) 0 (0.70)
Adjustment
 Adjusted 4 4.56 (2.64–7.88) 48.9% (0.12)
 Crude 4 5.18 (2.94–9.11) 24.4% (0.27)